tbuckley/cabot-search huggingface dataset:
Expanded left-side pleuropneumonectomy with resection and prosthetis of chest aorta and resection of pulmonary trunk in patient with lung cancer invading aorta and pulmonary trunk: Case report
Authors: Dmitry Bazarov, Vladimir Parshin, Yuriy Belov, Roman Komarov
Journal: European Respiratory Journal (2013)

Development of cardiac technologies and their introduction in practice of thoracic surgery allows to revise significantly indications to expanded one-stage surgery towards their expansion. Such operations still carry to casuistic.  The patient M., 53 yo arrived with complaints to pain in the left part thorax, cough, periodic blood spitting.  At a computer tomography with iv contrasting diagnosed central tumor of left lung with invading to aorta (A) and pulmonary trunk (PT). Bronchoscopy revealed infiltration of left B1+2 and B3. We performed expanded left-side pleuropneumonectomy with a mediastinal limfodissection, with a resection and plastics of PT with patch, a resection of descending part of A and its prosthetics by Vascutec 18 mm, a resection and plasticity of pericardium, a resection of left diafragm nerve in conditions of artificial blood circulation.  Planned morphological research of an operational material, including immunohistochemical research, diagnosed a neuroendocrine cancer with germination in the main left bronchus, adventition of aorta, wall of a pulmonary trunk. Metastasises in lymph nodes N2 not found. The patient discharged in 16th day p.o.  Conclusion. Case report shows correctness of multidisciplinary approach in the combined treatment of avdanced LC complicated by infiltration of large vessels, including PT and A, allow to perform radical treatment of such patients with satisfactory results. Any doubts in possibility of development of intraoperative complications have to be considered in favor of early inclusion of extracorporeal circulation.
Induction of Tumors in Adult Hamsters With Simian Virus 40
Authors: A. C. Allison, F. C. Chesterman, S. Baron
Journal: JNCI Journal of the National Cancer Institute (1967)

Certain effects of age and route of inoculation on simian virus 40 (SV40) tumor formation in Syrian hamsters have been examined. Approximately 20% of hamsters 4 months of age inoculated subcutaneously with virus developed tumors at the sites of inoculation after very long latent periods. Some tumors were transplantable and contained SV40 complement-fixing and transplantation antigens. In 4-month-old hamsters inoculated with virus directly into the cheek pouch, and in irradiated animals of this age inoculated subcutaneously, tumors appeared much sooner and in somewhat higher frequency than in intact animals inoculated subcutaneously. It is concluded that the resistance of adult animals to virus oncogenesis is relative, not absolute, and that potentially malignant cells can remain dormant for the greater part of the lifespan of the animals. Procedures that diminish the effectiveness of the host's immune response favor emergence of tumor cells.
Chronic compartment syndrome of the forearm in competitive motor cyclists: a report of two cases
Authors: J N Goubier, G Saillant
Journal: British Journal of Sports Medicine (2003)

Exertional compartment syndrome of the forearm is rare. However, it should be considered in cases of a painful forearm during motorcycle racing. Pressure measurements of all compartments during exercises that simulate the actions of racing confirm the diagnosis. An exertional electromyography may be useful to reveal a nerve compression associated with the compartment syndrome. Fasciotomy of the affected compartments allows relief of symptoms and return to previous activities in all cases.
Phase II trial of high-dose melphalan and autologous bone marrow transplantation for metastatic colon carcinoma.
Authors: R S Leff, J M Thompson, D B Johnson, K R Mosley, M B Daly, W A Knight, R L Ruxer, G L Messerschmidt
Journal: Journal of Clinical Oncology (1986)

Colon carcinoma, the second leading cause of cancer-related deaths in the United States, is resistant to chemotherapy in a large majority of cases. Single-agent and combination chemotherapy have failed to prolong survival. New approaches are clearly needed. In experimental models, a steep dose-response curve for colorectal cancer has been demonstrated using various agents. The hematopoietic toxicity of high-dose therapy with these drugs can be circumvented by autologous bone marrow transplantation. We investigated the use of high-dose melphalan with autologous bone marrow rescue in 20 patients with metastatic colon carcinoma. Each patient received melphalan, 180 mg/m2 intravenously (IV), followed eight hours later by bone marrow infusion. Median duration of granulocytopenia (less than 500 neutrophils/microL) was twelve days (range, 5 to 35 days), while transfusion-dependent thrombocytopenia (less than 20,000 platelets/microL) had a median duration of eight days (range, 3 to 23 days). Time to bone marrow engraftment was not affected by prior 5-fluorouracil therapy. Nausea and vomiting occurred in 14 patients but was generally short lived. Mild stomatitis, esophagitis, and diarrhea were common. Severe gastrointestinal (GI) side effects did not occur. One treatment-related death occurred secondary to intramural tumor necrosis, which resulted in massive lower GI bleeding. Complete responses were observed in three patients (15%) and partial responses in six patients (30%), for an overall response rate of 45%. Median survival was 198 days in this group of patients with extensive disease. High-dose melphalan therapy for metastatic colon carcinoma, when used with autologous bone marrow transplantation, appears to achieve a high response rate with tolerable toxicity. Further investigation is needed to define the role of this therapy in the care of advanced colon carcinoma.
Prospective Randomized Trial of Interferon Alfa-2a Plus Vinblastine Versus Vinblastine Alone in Patients With Advanced Renal Cell Cancer
Authors: Seppo Pyrhönen, Eeva Salminen, Mirja Ruutu, Timo Lehtonen, Martti Nurmi, Teuvo Tammela, Harri Juusela, Erkki Rintala, Päivi Hietanen, Pirko-Liisa Kellokumpu-Lehtinen
Journal: Journal of Clinical Oncology (1999)

PURPOSE: The combination of interferon alfa-2a (IFNα2a) plus vinblastine (VLB) induces objective tumor responses in patients with advanced renal cell cancer. However, no prospective randomized trial has shown that this treatment prolongs overall survival. We compared overall survival after treatment with IFNα2a plus VLB versus VLB alone in patients with advanced renal cell cancer. PATIENTS AND METHODS: We prospectively randomized 160 patients with locally advanced or metastatic renal cell cancer to receive either VLB alone or IFNα2a plus VLB for 12 months or until progression of disease. In both groups, VLB was administered intravenously at 0.1 mg/kg every 3 weeks, and in the combination group IFNα2a was administered subcutaneously at 3 million units three times a week for 1 week, and 18 million units three times a week thereafter for the second and subsequent weeks. For patients unable totolerate IFNα2a at 18 million units per injection, the dose was reduced to 9 million units. RESULTS: Median survival was 67.6 weeks for the 79 patients receiving IFNα2a plus VLB and 37.8 weeks for the 81 patients treated with VLB (P = .0049). Overall response rates were 16.5% for patients treated with IFNα2a plus VLB and 2.5% for patients treated with VLB alone (P = .0025). Treatment with the combination was associated with constitutional symptoms and abnormalities in laboratory parameters, but no toxic deaths were reported. CONCLUSION: The combination of IFNα2a plus VLB is superior to VLB alone in the treatment of patients with locally advanced or metastatic renal cell carcinoma. This is the first study to demonstrate that survival can be prolonged by using IFNα2a for these patients.
Haemarthrosis Aspiration in Treatment of Anterior Dislocation of the Shoulder
Authors: N P Trimmings
Journal: Journal of the Royal Society of Medicine (1985)

The beneficial effect of haemarthrosis aspiration in 13 women and one man aged over 60 years following anterior dislocation of the shoulder was compared with non-aspiration in a similar group of patients matched for age and sex. The results showed a consistent reduction in pain, early increased range of movement and earlier return of functional activity in the aspirated group. It is proposed that this simple therapeutic procedure be used to aid rehabilitation in the over-60 age group following anterior dislocation of the shoulder.
Bronchial hyperactivity in perimenstrual asthma is higher than in non-PMA asthmatics and correlates with sputum levels of eotaxin and IL-4
Authors: Szymon Skoczynski, Aleksandra Semik-Orzech, Ewa Sozanska, Wojciech Szanecki, Michal Majewski, Krzysztof Kolodziejczyk, Andrzej Witek, Wladyslaw Pierzchala
Journal: European Respiratory Journal (2014)

Background  Although perimenstrual asthma (PMA) has been documented in up to 40% of asthmatic women and is often associated with severe and unstable course of the disease, studies on PMA are still inconsistent.   Objectives  To compare levels of bronchial hyperactivity (BHR) to metacholine between premenopausal PMA and non-PMA asthmatic women in relation to sputum concentration of proinflammatory cytokines.   Methods  Premenopausal women with regular menstrual exacerbations diagnosed as: PMA (n= 12), non-PMA asthmatics (n=9), and healthy controls (n=10) were prospectively followed over 2 consecutive menstrual cycles. Prior to study airway responsiveness to methacholine was performed in each subject. Total IgE blood concentrations as well, as sputum induction were determined in the 10 th  and 26 th  day of each of the two cycles. Sputum concentration of: eotaxin, IL-1β, IL-4, IL-10 were measured by ELISA.   Results  Levels of BHR to metacholine as well, as total blood IgE concentrations in PMA subjects were significantly higher than in non-PMA asthmatics and healthy controls (p=0.001, p=0.02 respectively) and correlated with each other (p=0.04, r=0.86). Sputum eotaxin and IL-4 concentrations in both, luteal and follicular phase were increased in PMA patients when compared with non-PMA asthmatics (p=0.02, p=0.04, respectively). No differences as far as sputum levels of IL-10 between groups were noticed.   Conclusions  BHR level in PMA is higher than in non-PMA asthmatics and correlates with increased total IgE concentration. The increased level of BHR in PMA patients is associated with a shift in the type-1/type-2 cytokine balance toward a type-2 response.
Isolation and Initial Characterization of Tumoricidal Monokine(s) From the Human Monocytic Leukemia Cell Line THP-1&lt;xref ref-type="fn" rid="FN2"&gt;2&lt;/xref&gt;
Authors: C A Armstrong, J Klostergaard, G A Granger
Journal: JNCI Journal of the National Cancer Institute (1985)

A cloned subline of the human monocytic leukemia cell line, THP-1, was induced to produce high levels of cytotoxic activity following an 18-hour phorbol myristate acetate (CAS: 16561-29-8) stimulation in vitro. This activity, termed monocyte cell line cytotoxin(s) (MCCT), was tested in vitro on different human continuous cell lines (Chang, ESH-7, GM3104A, HeLa, HT-1080, K562, Mel, T-24) and on primary human fibroblasts (GM3468, Manz). The continuous cell lines exhibited a spectrum of sensitivity to MCCT-containing supernatants whereas the primary fibroblasts were resistant to lysis. Enzymatic degradation and heat denaturation studies indicate that MCCT is a protein. Its bioactivity can be resolved into three lytic peaks after molecular sieving on Ultrogel AcA 44. The major peak, designated alpha MCCT, eluted with a molecular weight of 100,000-140,000 daltons. A minor peak, beta MCCT, was seen at 60,000-80,000 daltons, and a third, unstable minor peak, gamma MCCT, eluted at less than 10,000 daltons. The alpha-lytic peak was examined further and was found to migrate as a single peak in 7% native polyacrylamide gel electrolysis tube gels with an rf of 0.25-0.30. None of the MCCT forms were immunologically cross-reactive with human alpha-lymphotoxin. Various protease inhibitors known to inhibit monokine- and macrophage-mediated direct cell lysis in vitro were tested for their inhibitory effects on alpha MCCT activity. The irreversible binding inhibitor N alpha-p-tosyl-L-lysyl chloromethyl ketone inhibited the biologic activity of alpha MCCT. The reversible binding inhibitors N alpha-p-tosyl-L-arginine methyl ester and soybean trypsin inhibitor were able to block in vitro lytic activity when added to alpha MCCT in the presence of the target cell. In contrast, the inhibitors phenylmethylsulfonyl fluoride, L-1-tosylamide, 2-phenylethyl chloromethyl ketone, and N alpha-acetyl-L-lysine methyl ester were not effective in blocking cytolysis. Finally, the hydrogen peroxide scavenger catalase inhibited alpha MCCT lytic activity in vitro; however, the hypochlorous acid scavengers alanine, serine, and valine were without effect.
Spontaneous Tumors and Common Diseases in Two Colonies of Syrian Hamsters. I. Incidence and Sites2
Authors: Parviz Pour, Norbert Kmoch, Eberhard Greiser, Ulrich Mohr, Jürgen Althoff, Antonio Cardesa
Journal: JNCI Journal of the National Cancer Institute (1976)

Journal Article Spontaneous Tumors and Common Diseases in Two Colonies of Syrian Hamsters. I. Incidence and Sites Get access Parviz Pour, Parviz Pour Search for other works by this author on: Oxford Academic PubMed Google Scholar Norbert Kmoch, Norbert Kmoch Search for other works by this author on: Oxford Academic PubMed Google Scholar Eberhard Greiser, Eberhard Greiser Search for other works by this author on: Oxford Academic PubMed Google Scholar Ulrich Mohr, Ulrich Mohr Search for other works by this author on: Oxford Academic PubMed Google Scholar Jürgen Althoff, Jürgen Althoff Search for other works by this author on: Oxford Academic PubMed Google Scholar Antonio Cardesa Antonio Cardesa Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 56, Issue 5, May 1976, Pages 931–935, https://doi.org/10.1093/jnci/56.5.931 Published: 01 May 1976 Article history Received: 01 May 1975 Accepted: 17 October 1975 Published: 01 May 1976
Kruppel-like factor 4 is critical for transcriptional control of cardiac mitochondrial homeostasis
Authors: Xudong Liao, Rongli Zhang, Yuan Lu, Domenick A. Prosdocimo, Panjamaporn Sangwung, Lilei Zhang, Guangjin Zhou, Puneet Anand, Ling Lai, Teresa C. Leone, Hisashi Fujioka, Fang Ye, Mariana G. Rosca, Charles L. Hoppel, P. Christian Schulze, E. Dale Abel, Jonathan S. Stamler, Daniel P. Kelly, Mukesh K. Jain
Journal: Journal of Clinical Investigation (2015)

Mitochondrial homeostasis is critical for tissue health, and mitochondrial dysfunction contributes to numerous diseases, including heart failure. Here, we have shown that the transcription factor Kruppel-like factor 4 (KLF4) governs mitochondrial biogenesis, metabolic function, dynamics, and autophagic clearance. Adult mice with cardiac-specific Klf4 deficiency developed cardiac dysfunction with aging or in response to pressure overload that was characterized by reduced myocardial ATP levels, elevated ROS, and marked alterations in mitochondrial shape, size, ultrastructure, and alignment. Evaluation of mitochondria isolated from KLF4-deficient hearts revealed a reduced respiration rate that is likely due to defects in electron transport chain complex I. Further, cardiac-specific, embryonic Klf4 deletion resulted in postnatal premature mortality, impaired mitochondrial biogenesis, and altered mitochondrial maturation. We determined that KLF4 binds to, cooperates with, and is requisite for optimal function of the estrogen-related receptor/PPARγ coactivator 1 (ERR/PGC-1) transcriptional regulatory module on metabolic and mitochondrial targets. Finally, we found that KLF4 regulates autophagy flux through transcriptional regulation of a broad array of autophagy genes in cardiomyocytes. Collectively, these findings identify KLF4 as a nodal transcriptional regulator of mitochondrial homeostasis.
Posttransplant lymphoproliferative disorders not associated with Epstein-Barr virus: a distinct entity?
Authors: V Leblond, F Davi, F Charlotte, R Dorent, M O Bitker, L Sutton, I Gandjbakhch, J L Binet, M Raphael
Journal: Journal of Clinical Oncology (1998)

PURPOSE Organ recipients are at a high risk of posttransplant lymphoproliferative disorders (PTLD) as a result of immunosuppressive therapy. Most B-cell lymphomas are associated with Epstein-Barr virus (EBV) infection. We describe a morphologically and clinically distinct group of PTLD in 11 patients that occurred late after organ transplantation and were not associated with EBV. PATIENTS AND METHODS There were seven kidney, three heart, and one liver transplant recipients (group I). The clinical manifestations, pathologic findings, treatment, and outcome were compared with those in 21 patients with EBV-associated PTLD treated in our institution (group II). EBV was detected with at least two techniques: Epstein-Barr-encoded RNA (EBER) in situ hybridization with EBER 1 + 2 probes, Southern blotting, and detection of latent membrane protein 1 (LMP1) expression by immunohistochemistry. RESULTS The time between transplantation and the diagnosis of lymphoma ranged from 180 to 10,220 days in group I (mean, 2,234; median, 1,800) and from 60 to 2,100 days in group II (mean, 546; median, 180), and was significantly shorter in group II (P = .02). Among 19 tumors diagnosed within 2 years after the graft, 16 were associated with EBV; among 13 tumors diagnosed after more than 2 years, only five were associated with EBV. All of the B-cell PTLDs in group I were classified as monomorphic, meeting the criteria of B diffuse large-cell lymphoma (B-DLCL) with a component of immunoblasts, and genotyping confirmed their monoclonality. Three tumors were T-cell pleomorphic lymphomas. Tumor sites were mainly bone marrow and lymph nodes. Overall median survival was 1 month in group I and 37 months in group II, with two patients still alive in group I and nine in group II. The survival time was significantly longer in group II (P &lt; .01). CONCLUSION EBV-negative PTLD may be a late serious complication of organ transplantation. Half the tumors observed after kidney transplantation in our center were not associated with EBV and emerged after more than 5 years, which suggests the number of EBV-negative PTLDs in organ recipients might increase with time.
Pleurodesis with large-particle talc poudrage is safe in malignant pleural effusion
Authors: Marwan Najib
Journal: Thorax (2007)

▴ Janssen JP, Collier G, Astoul P, et al . Safety of pleurodesis with talc poudrage in malignant pleural effusion: a prospective cohort study. Lancet2007;369:1535–9.

[OpenUrl][1][CrossRef][2][PubMed][3][Web of Science][4]



Talc has been widely used for over 75 years as a sclerosing agent in patients with recurrent malignant pleural effusion. It is probably more effective than other agents, widely available and cheap with minimal side effects. However, recent concerns about patients developing acute respiratory distress syndrome (ARDS) have led to misgivings about its …

 [1]: {openurl}?query=rft.jtitle%253DLancet%26rft.stitle%253DLancet%26rft.aulast%253DJanssen%26rft.auinit1%253DJ.%2BP.%26rft.volume%253D369%26rft.issue%253D9572%26rft.spage%253D1535%26rft.epage%253D1539%26rft.atitle%253DSafety%2Bof%2Bpleurodesis%2Bwith%2Btalc%2Bpoudrage%2Bin%2Bmalignant%2Bpleural%2Beffusion%253A%2Ba%2Bprospective%2Bcohort%2Bstudy.%26rft_id%253Dinfo%253Adoi%252F10.1016%252FS0140-6736%252807%252960708-9%26rft_id%253Dinfo%253Apmid%252F17482984%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx
 [2]: /lookup/external-ref?access_num=10.1016/S0140-6736(07)60708-9&link_type=DOI
 [3]: /lookup/external-ref?access_num=17482984&link_type=MED&atom=%2Fthoraxjnl%2F62%2F10%2F897.atom
 [4]: /lookup/external-ref?access_num=000246215800027&link_type=ISI
Factors affecting growth after renal transplantation.
Authors: W E Harmon, K Jabs
Journal: Journal of the American Society of Nephrology (1992)

Renal transplantation has been recognized as the treatment of choice for children with chronic renal failure principally because it can normalize their physiologic status and thus provide them with the potential for normal growth. The results of renal transplantation, however, have been mixed with some reports of excellent posttransplant growth and others with less optimistic results. Some of the differences among these studies may be because of the use of multiple methods to assess the success or failure of posttransplant growth. The usual methods have included assessment of the final adult height, growth velocity, presence of accelerated growth rates, change in height standard deviation scores, and growth survival. All of these methods have advantages and disadvantages in the description of the success or failure of growth after renal transplantation, but no single method stands out as the most appropriate to use in all circumstances. Furthermore, growth is dependent on a large number of complex and interrelated factors. At least four of these factors have been shown to affect the growth rates of children after renal transplantation: age at the time of transplant; allograft function; the type, dose, and schedule of immunosuppressive medication; and other endocrinologic factors. Finally, analysis of long-term growth patterns in children after renal transplantation has shown that growth rates frequently decrease over time. Even children who have grown well immediately after the transplant may develop growth failure after several years. We conclude that the majority of children with renal transplants can experience normal or even accelerated growth rates after the procedure. Unfortunately, growth rates subsequently tend to decline in most children.(ABSTRACT TRUNCATED AT 250 WORDS)
Treatment of hairy-cell leukemia with cladribine: response, toxicity, and long-term follow-up.
Authors: M A Hoffman, D Janson, E Rose, K R Rai
Journal: Journal of Clinical Oncology (1997)

PURPOSE To analyze initial and long-term outcomes after treatment of patients with active hairy-cell leukemia (HCL) with a single cycle of cladribine (2-CdA). PATIENTS AND METHODS Forty-nine patients with active HCL were treated with 2-CdA by continuous intravenous infusion at 0.1 mg/kg/d for a total of 7 days at the Long Island Jewish Medical Center between September 1990 and August 1992. Here we report on all patients followed-up until April 1996. RESULTS At 3 months after treatment, complete response (CR) occurred in 37 patients (76%) and partial response (PR) occurred in 12 patients (24%), for an overall response rate of 100% (95% confidence interval, 94% to 100%). At a median follow-up of 55 months, the relapse-free survival is 80% and overall survival is 95%. Ten patients (20%) have relapsed. Of the 26 patients in whom lymphocyte phenotyping was performed, four were found to have a CD25-negative phenotype. All four of these patients had PRs only and all relapsed. Eight patients have been re-treated with 2-CdA, and all achieved at least a partial remission; two of these have already relapsed with remission durations of less than 1 year. Five second malignancies have occurred in four patients. CONCLUSION With a median follow-up of more than 4 years, 39 patients (80%) continue in remission. Only two deaths have occurred. A CD25-negative phenotype may predict for a poorer response to 2-CdA. Patients who relapse may be re-treated with 2-CdA, but subsequent remissions may be of shorter duration. There has not been a markedly increased incidence of second malignancies or late opportunistic infections.